Market Access Impact (EU5) [RA]
Eliminating market barriers could help one brand almost double its market share
Market barriers have a modest but significant effect on rheumatoid arthritis (RA) prescriptions in the EU5. The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, where certain brands are poised to nearly double market share.
Find out which barriers are costing your brand market share in: Market Access Impact: Rheumatoid Arthritis (EU5).
Based on a survey of 150 rheumatologists, the report covers 12 major therapies from AbbVie, Biogen, Bristol-Myers Squibb, Merck Sharp & Dohme, Mundipharma, Napp, Pfizer, Roche, and UCB. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.
Reasons to Purchase
- Nearly all brands are widely prescribed. Over 60% or more of the doctors surveyed prescribe nine of the 12 brands covered, and over 90% prescribe the top brand.
- Six brands gain share. Two of them gain significantly while the other two barely gain at all.
- Biosimilars are beginning to have an impact. The most prescribed biosimilar gains the most share overall, but others are struggling to capture physician interest.
- Eliminating barriers would have the most impact on the bottom of the market. The brand that is prescribed the least is set to double its market share and move into 9th place.
- Three brands have perception problems. Just over 20% of doctors surveyed would not consider prescribing those brands.
- Market access is not the problem. Barriers related to market access affect far fewer prescriptions than either of the top two barriers.
Insight into 12 major RA drugs
- Benepali (etanercept; Biogen)
- Cimzia (certolizumab pegol; UCB)
- Enbrel (etanercept; Pfizer)
- Humira (adalimumab; AbbVie)
- Inflectra (infliximab; Pfizer)
- MabThera (rituximab; Roche)
- Orencia (abatacept; Bristol-Myers Squibb)
- Remicade (infliximab; Merck Sharp & Dohme)
- Remsima (infliximab; Napp/Mundipharma)
- RoActemra (tocilizumab; Roche)
- Simponi (golimumab; Merck Sharp & Dohme)
- Xeljanz (tofacitinib; Pfizer)
Exploring Market Access Barriers
Market Access Impact: Market Access Impact: Rheumatoid Arthritis (EU5) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
>How barriers affect your brand:
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 150 rheumatologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
- Have been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients in total in the last month
We conducted the survey between November 3-9, 2017.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.